AICHI MEDICAL UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1971-01-01
- Employees
- -
- Market Cap
- -
Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.
Phase 1
- Conditions
- Solid Tumor
- Interventions
- Biological: Mogamulizumab
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Aichi Medical University
- Target Recruit Count
- 58
- Registration Number
- NCT01929486
- Locations
- 🇯🇵
Aichi Medical University, Nagoya, Aichi, Japan
© Copyright 2025. All Rights Reserved by MedPath